colli
Senior Member
Joined:September 2013
Posts: 296
Location:
Likes: 236
Recent Posts
Last Online Nov 10, 2024 6:47:48 GMT
|
Post by colli on Sept 4, 2014 17:33:26 GMT
my first look at wiki shows his conflict of interests, Now i dont believe everything in wiki but there is too much there to asume he is not in the BP pockets..
"quoted from site"
Financial Conflict of Interest (FCOI)[edit] As of June 2013, as disclosed in publications in Annals of Internal Medicine, British Journal of Psychiatry, and JAMA Lieberman’s disclosure of financial conflict of interest is on file with the International Committee of Medical Journal Editors (ICMJE). ICMJE disclosure and review includes FCOI categories: research grants/industry ties, consulting and honorarium, participation in Data Safety Monitoring Boards (DSMB), provision of research meds or equipment, writing/royalties, administrative support, expert testimony, speakers bureaus, patents, stocks and stock options, travel.[5]
A note on "competing interests" for contributors to the book Essentials of Schizophrenia (2011) says Lieberman receives no direct financial compensation for his research, consulting and advisory board activities (except Intra-Cellular Therapies [which has no asterisk]).[6]
In 2006, Lieberman co-signed a letter to the editor of The Wall Street Journal with about thirty other doctors. With this, he disclosed honoraria, consulting fees, research grant support from AstraZeneca, Bristol-Myers Squibb, Upjohn Pharmacia, Novartis, Eli Lilly, Janssen, Pfizer, Hoechst AG, and AstraZeneca. He also listed as corporate speakers bureaus AstraZeneca, Janssen, Eli Lilly, and Pfizer.[7] Lieberman disclosed in 2007 in the journal Primary Psychiatry that he was a consultant to Eli Lilly and Pfizer. He was on the advisory boards of AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, and Pfizer. He has a patent from Repligen Corporation. Lieberman received research support from Acadia, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck, Organon, and Pfizer.[8] In 2009, Lieberman disclosed grants from Allon, Forest Laboratories, Merck, Pfizer, AstraZeneca, Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Janssen, Otsuka, Solvay, and Wyeth to the American College of Neuropsychopharmacology for their annual meeting in which he participated.[9] In 2011, his disclosure at Medscape of relevant financial relationships says he served on the advisory board of Bioline, GlaxoSmithKline, Intra-Cellular Therapies, Eli Lilly, Pierre Fabre, and Psychogenics, and that he received research grants from Allon Therapeutics, GlaxoSmithKline, Ortho-McNeil-Janssen, Merck, Novartis, Pfizer, Sepracor, and Targacept.[10] He also disclosed in 2013, as a member of the psychiatry editorial board at Medscape, that he received research grants from Allon, Novartis, Sepracor, and Targacept; and he served on the advisory boards at Bioline, Intra-Cellular Therapies, Pierre Fabre and Psychogenics.[11] In additional disclosures at Medscape in 2013, he received research grants from Allon, GlaxoSmithKline, Eli Lilly, Merck, Novartis, Pfizer, Psychogenics, Hoffmann-La Roche, Sepracor, and Targacept, and he served on the advisory board of Alkermes, Bioline, Intra-Cellular Therapies, Pierre Fabre, and Psychogenics.[12]
|